Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aztreonam-avibactam vs best available therapy for serious MBL-producing gram-negative infections
CTR20211126Phase 3Terminated
- Sponsor
- Pfizer
- Start
- May 2021
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of aztreonam, avibactam in Intra-abdominal infection (IAI), hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), complicated urinary tract infection (cUTI), bloodstream infection (BSI), sponsored by Pfizer. Started May 2021; status: terminated.
02
Drugs
aztreonamavibactam
03
Conditions
Intra-abdominal infection (IAI)hospital-acquired pneumonia (HAP)ventilator-associated pneumonia (VAP)complicated urinary tract infection (cUTI)bloodstream infection (BSI)
Beyond the preview
Go deeper on CTR20211126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211126.